Page last updated: 2024-11-04

vorinostat and Arachnoidal Cerebellar Sarcoma, Circumscribed

vorinostat has been researched along with Arachnoidal Cerebellar Sarcoma, Circumscribed in 12 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research Excerpts

ExcerptRelevanceReference
"The treatment with AMG 900 increased the p21 and GDF15 expression, but did not alter the TP53 in one of the cell lines."5.42Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines. ( Andrade, AF; Borges, KS; Geron, L; Scrideli, CA; Suazo, VK; Tone, LG, 2015)
"The treatment with AMG 900 increased the p21 and GDF15 expression, but did not alter the TP53 in one of the cell lines."1.42Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines. ( Andrade, AF; Borges, KS; Geron, L; Scrideli, CA; Suazo, VK; Tone, LG, 2015)
"Several cancers, however, fail to respond to TRAIL's antineoplastic effects."1.38Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation. ( Beck, JF; Becker, S; Grauel, D; Palani, CD; Sonnemann, J; Trommer, N; Wittig, S, 2012)
"Medulloblastoma is a malignant pediatric brain tumor."1.38REST is a novel prognostic factor and therapeutic target for medulloblastoma. ( Cooper, L; Fangusaro, J; Goldman, S; Gopalakrishnan, V; Hasselblatt, M; Helenowski, IB; Laureano, A; MacDonald, T; Rajaram, V; Riedemann, L; Taylor, P, 2012)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (33.33)29.6817
2010's6 (50.00)24.3611
2020's2 (16.67)2.80

Authors

AuthorsStudies
Nawar, N1
Bukhari, S1
Adile, AA1
Suk, Y1
Manaswiyoungkul, P1
Toutah, K1
Olaoye, OO1
Raouf, YS1
Sedighi, A1
Garcha, HK1
Hassan, MM1
Gwynne, W1
Israelian, J1
Radu, TB1
Geletu, M1
Abdeldayem, A1
Gawel, JM1
Cabral, AD1
Venugopal, C1
de Araujo, ED1
Singh, SK1
Gunning, PT1
Leary, SES1
Kilburn, L1
Geyer, JR1
Kocak, M1
Huang, J1
Smith, KS1
Hadley, J1
Ermoian, R1
MacDonald, TJ1
Goldman, S2
Phillips, P1
Young Poussaint, T1
Olson, JM3
Ellison, DW1
Dunkel, IJ1
Fouladi, M1
Onar-Thomas, A1
Northcott, PA1
Geron, L1
Borges, KS1
Andrade, AF1
Suazo, VK1
Scrideli, CA1
Tone, LG1
Patties, I1
Kortmann, RD1
Menzel, F1
Glasow, A1
Häcker, S1
Dittrich, A1
Mohr, A1
Schweitzer, T1
Rutkowski, S1
Krauss, J1
Debatin, KM1
Fulda, S1
Canettieri, G1
Di Marcotullio, L1
Coni, S1
Greco, A1
Gulino, A1
Sonnemann, J2
Trommer, N1
Becker, S1
Wittig, S1
Grauel, D1
Palani, CD1
Beck, JF2
Muscal, JA1
Scorsone, KA1
Zhang, L1
Ecsedy, JA1
Berg, SL1
Taylor, P1
Fangusaro, J1
Rajaram, V1
Helenowski, IB1
MacDonald, T1
Hasselblatt, M1
Riedemann, L1
Laureano, A1
Cooper, L1
Gopalakrishnan, V1
Kumar, KS1
Heesch, S1
Müller, C1
Hartwig, C1
Maass, M1
Bader, P1
Spiller, SE2
Ravanpay, AC1
Hahn, AW1
Ditzler, SH1
Pullar, BJ1

Trials

1 trial available for vorinostat and Arachnoidal Cerebellar Sarcoma, Circumscribed

ArticleYear
Vorinostat and isotretinoin with chemotherapy in young children with embryonal brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC-026).
    Neuro-oncology, 2022, 07-01, Volume: 24, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cerebellar Neoplasms; Child; Child,

2022

Other Studies

11 other studies available for vorinostat and Arachnoidal Cerebellar Sarcoma, Circumscribed

ArticleYear
Discovery of HDAC6-Selective Inhibitor NN-390 with
    Journal of medicinal chemistry, 2022, 02-24, Volume: 65, Issue:4

    Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Computer Simulation; Drug D

2022
Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines.
    Neurological research, 2015, Volume: 37, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Child; Cycl

2015
Enhanced inhibition of clonogenic survival of human medulloblastoma cells by multimodal treatment with ionizing irradiation, epigenetic modifiers, and differentiation-inducing drugs.
    Journal of experimental & clinical cancer research : CR, 2016, 06-17, Volume: 35, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Di

2016
Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
    Oncogene, 2009, Sep-03, Volume: 28, Issue:35

    Topics: Benzamides; Caspase 8; Cell Line, Tumor; Cell Survival; Cerebellar Neoplasms; Drug Combinations; Dru

2009
Turning off the switch in medulloblastoma: the inhibitory acetylation of an oncogene.
    Cell cycle (Georgetown, Tex.), 2010, Jun-01, Volume: 9, Issue:11

    Topics: Acetylation; Cerebellar Neoplasms; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hyd

2010
Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation.
    Cancer biology & therapy, 2012, Volume: 13, Issue:6

    Topics: Apoptosis; Bone Neoplasms; Caspase 8; Cell Line, Tumor; Enzyme Activation; Histone Deacetylase Inhib

2012
Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.
    Investigational new drugs, 2013, Volume: 31, Issue:1

    Topics: Antineoplastic Agents; Aurora Kinase B; Aurora Kinases; Azepines; Cell Line, Tumor; Cell Survival; D

2013
REST is a novel prognostic factor and therapeutic target for medulloblastoma.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:8

    Topics: Adolescent; Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cereb

2012
Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.
    International journal of oncology, 2006, Volume: 28, Issue:3

    Topics: Acetylation; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Butyrates; Caspase 3;

2006
Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma.
    Journal of neuro-oncology, 2006, Volume: 79, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cells, Cultured; Cerebellar Neoplasms; Child; Fibroblasts

2006
Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA).
    Journal of neuro-oncology, 2008, Volume: 87, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Morphogenetic Protein 2; Bo

2008